The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer

The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer

Trastuzumab is a humanized mAb used to treat HER2-overexpressing breast cancer; however its mechanisms remain to be fully elucidated. Previous studies suggest a role for immunity in mediating trastuzumab-specific antitumor effects. This study evaluated the role(s) of trastuzumab and other antibodies...

Full description

Bibliographic Details
Main Authors: Xiaochen Hu, Yiwen Liu, Xiusen Zhang, Dejiu Kong, Jinyu Kong, Di Zhao, Yibo Guo, Lingyun Sun, Luoyi Chu, Shupei Liu, Xurong Hou, Feng Ren, Ying Zhao, Chengbiao Lu, Desheng Zhai, Xiang Yuan
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
HER2+ breast cancer
Trastuzumab
Macrophages
ADCP
B7-H4
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558620301457

Internet

http://www.sciencedirect.com/science/article/pii/S1476558620301457

Similar Items